Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor . In Vitro Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. Raxatrigine (GSK-1014802) received orphan-drug designation from the US Food and Drug Administration in July 2013. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Sodium channel blocker
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Raxatrigine
CAS number：934240-30-9 molecular formula：C18H19FN2O2
overview
compound introduction
Specs
| Chinese alias | 拉沙三嗪 | ||
| English alias | N-{2-oxo-2-[(3S)-3-{[(1s,4s)-4-hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexyl]amino}pyrrolidin-1-yl]ethyl}-3-(trifluoromethyl)benzamide | DB11706 | 2,6-Nonadienoic acid, 7-ethyl-9-[(2R,3S)-3-ethyl-3-methyloxiranyl]-3-methyl-, methyl ester, (2E,6E)- | ||
| CAS number | 934240-30-9 | molecular formula | C18H19FN2O2 |
| molecular weight | 314.4 g/mol | Exact mass | ≥99% |
| PSA | 64.400 Ų | logp | 2.4 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
